CTIS2022-501504-95-00进行中（未招募）1 期
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE - ARIADNE
Karolinska University Hospital0 个研究点目标入组 330 人开始时间: 2022年12月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Women or men 18 years or older, Negative serum pregnancy test for women of childbearing potential or for patients who have experienced menopause onset <12 months prior to randomisation, Patients of childbearing potential must be willing to use one highly effective contraception or two effective forms of nonhormonal contraception., Participants must be able to communicate with the investigator and comply with the requirements of the study procedures, Written informed consent must be given according to ICH/GCP, and national/local regulations, Histologically confirmed breast cancer with an invasive component measuring = 20 mm and/or with morphologically confirmed spread to regional lymph nodes (stage cT2-cT4 with any cN, or cN1-cN3 with any cT), Performance status 0 or 1 at the time of randomisation, Known estrogen-receptor and/or progesterone receptor status, as assessed locally by IHC. The cut-off for positivity for ER/PR for this study is at least 10% of cell nuclei staining for ER or PR, respectively, Known HER2-positive breast cancer, Left Ventricular Ejection Fraction (LVEF) = 50%, Adequate bone-marrow, hepatic and renal function, Availability of tumor and blood samples as described in the protocol
排除标准
- •Participation in other interventional trials, Concomitant medication(s) with a known risk to prolong the QT interval, Pregnant or breastfeeding female patients, or patients who are planning to become pregnant, History of (non-infectious) Interstitial Lung Disease (ILD) / pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening., Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), Any autoimmune, connective tissue or inflammatory disorders (e.g. Rheumatoid arthritis, Sjogren's, sarcoidosis etc.) where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for patients who are included in the study., Prior pneumonectomy, History of positive testing for HIV or known AIDS, Acute or chronic infection with hepatitis B or C virus, Any impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)., Receipt of live, attenuated vaccine within 30 days prior to the first dose of trastuzumab deruxtecan. Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study drug, Pre-treatment axillary surgery, Any psychological, including substance abuse, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial., Allergic reactions or hypersensitivity to the study drugs or other monoclonal antibodies, Administration of other experimental drugs, either concomitantly or during the past 30 days before treatment initiation, A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART)., Recent major surgery, Presence of distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum, Other malignancy diagnosed during the past five years, History of invasive breast cancer, History of DCIS, except for patients treated exclusively with mastectomy >5 years prior to diagnosis of current breast cancer, Active cardiac disease or a history of cardiac dysfunction, Patients with ER-positive breast cancer being treated with drugs recognized as strong inhibitors or inducers of the isoenzyme CYP3A which cannot be discontinued at least 7 days prior to planned treatment with ribociclib.
研究者
相似试验
进行中（未招募）
不适用
SPONTANEOUS STUDY WITH ADJUVANT TRASTUZUMAB HERCEPTIN IN WOMEN WITH HER-2 POSITIVE PRIMARY BREAST CANCER WHO HAVE COMPLETED ADJUVANT CHEMOTHERAPY - HERMAEUCTR2005-005274-71-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO20
已完成
不适用
Effect of classical music in pain, mood and anxiety in terminally ill / cancer patientsPain in terminally ill / cancer patientsSLCTR/2016/006Dr Buddhika Vidanagama
尚未招募
不适用
Role of topical Tranexamic acid versus topical Epinephrine on bleeding control in Endoscopic Ear SurgeriesCTRI/2021/10/037170Dr Asutosh Adhikari
进行中（未招募）
1 期
Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritisPatients with medical diagnosis of Rheumatoid ArthritisEUCTR2004-004893-96-GBHammersmith Hospitals NHS trust50
尚未招募
2 期
Device Stimulation for Episodic MigraineCTRI/2023/10/058543Dept of Neurology